

Annual Shareholders' Meeting 2026

Siemens Healthineers Prepares Shareholders for a Pivotal Year

- **Start of the "Elevating Health Globally" strategy phase**
- **Possible deconsolidation makes Siemens Healthineers a more attractive investment**
- **Increased dividend of €1.00 per share for fiscal year 2025 approved**
- **Large majority in favor of the management's resolution proposals on all further agenda items**

Siemens Healthineers AG prepared investors at its annual shareholders' meeting for a pivotal year, marked by a new strategy phase and the preparations for a possible deconsolidation by Siemens AG of its stake in Siemens Healthineers. "2026 will be a year of special significance for our company," said Chief Executive Bernd Montag during the annual shareholders' meeting. "On the one hand, 2026 marks the beginning of our new strategy phase 'Elevating Health Globally' in which we want to help raise healthcare to a new level worldwide. On the other hand, after a potential deconsolidation we want to be an attractive investment for more shareholders than ever before."

Supervisory Board Chair Ralf Thomas, who is also chief financial officer of Siemens AG, elaborated on Siemens' plan to divest its majority stake in Siemens Healthineers and to reduce the shareholding to a financial stake in the medium term. "Particular benefits of the planned transaction for both companies would include increased possibilities for strategic development as well as a significantly higher transparency and a reduction in complexity for the capital market. Both the planned transaction and the new 'Elevating' strategy phase serve to further advance the position of Siemens Healthineers as a global leader in medical technology," said Thomas.

Dementia, stroke, heart attack and cancer in focus

The strategic focus of Siemens Healthineers over the next five years will center on the continued global increase in the non-communicable diseases stroke, neurodegenerative diseases, cardiovascular diseases and cancer. Three-quarters of all deaths today are due to these diseases. Healthcare systems around the world are tasked with finding personalized treatment pathways for a rapidly growing number of patients –

all while contending with a lack of skilled workers and limited budgets. Siemens Healthineers supports its customers around the globe in meeting this challenge.

The combination almost five years ago with cancer specialist Varian has made the company even stronger. As part of Siemens Healthineers, Varian has been able to significantly expand its innovation leadership and has greatly benefited from an international presence and access to healthcare decision makers. This has enabled Varian to increase its market share by 10 percentage points since 2021 to above 60 percent. “Imaging and Precision Therapy – supported by artificial intelligence – form the highly synergetic core of our company. Diagnostics, on the other hand, has few synergies with the other segments. The next step is now for Diagnostics to consistently pursue its own strategy – and derived from that, its own independent structure,” said Montag.

Payout ratio 52 percent of net income

The annual shareholders’ meeting approved all agenda items with a large majority. Among other items, the shareholders followed the proposal of the managing board and the supervisory board to pay an increased dividend of €1.00 per share entitled to the dividend for fiscal year 2025. This corresponds to a total payment of around €1.117 billion and a payout ratio of around 52 percent of net income.

“Siemens Healthineers once again set itself very ambitious goals and has achieved them,” said Supervisory Board Chair Ralf Thomas, looking back at fiscal year 2025, for which the acts of the managing board and supervisory board members were ratified by a large majority. Despite the challenging geopolitical and macroeconomic environment, the entire Healthineers team kept the impact of these crises on the business and on global healthcare to a minimum, Thomas said.

The publicly broadcast virtual annual shareholders’ meeting was followed by 1202 people at its peak. 111 questions were asked by shareholders or their proxies by way of video communication and were answered by the managing board and supervisory board.

The individual voting results on the agenda items of the annual shareholders’ meeting can be found [here](#).

Press photos and further information can be found [here](#).

Media contact

Georgina Prodhan

+44 7808828799; Georgina.Prodhan@siemens-healthineers.com

Ulrich Künzel

+49 162 2433492; Ulrich.Kuenzel@siemens-healthineers.com

Visit the [Siemens Healthineers Press Center](#).

Subscribe to our [“Medtech matters” newsletter on LinkedIn](#).

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at [siemens-healthineers.com](https://www.siemens-healthineers.com).